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Navdeep ChandelNavdeep Chandel took a BA in mathematics and a PhD
in cell physiology at University of Chicago, where he also
did his post-doctoral work, on cytochrome c oxidase.
The recognition of the role of mitochondria in activating
apoptosis and hypoxic responses led him to his present
research focus on mitochondria as signaling organelles
at Northwestern University, where he is a Professor of
Medicine and Cell Biology. What follows is the edited
and updated transcript of an interview he gave at the
Biomed Central conference on Metabolism, Diet and
Disease in May [1], where the topic was cancer and me-
tabolism and he spoke on the contentions surrounding
the issue of whether and how the antidiabetic drug met-
formin acts to inhibit tumor growth.Navdeep Chandel
There have been very high hopes for using
metformin and other biguanides against cancer.
How is that class of drug thought to work in cancer?
There are two ideas about how metformin works. Epi-
demiological studies on people taking metformin for dia-
betes suggested that they had a lower incidence of cancer,
and this was in multiple types of cancers. One obvious ef-
fect of metformin in people who have high levels of insu-
lin is that their insulin levels come down. That now has an
effect on the cancer cells.
What is that effect? Well, one big effect is because
insulin is a mitogen. Insulin and insulin growth factors
can activate a signaling kinase pathway that depends on
the PI3-kinase pathway. We know that is the growth
pathway. The data are very clear: in cancer and through-
out the metazoans, that’s how we grow.
So imagine that somebody has high levels of insulin,
and that metformin decreases those insulin levels. The
way metformin does that is it gets into the liver and pre-
vents gluconeogenesis from occurring, primarily. So your
liver is not putting out as much glucose, so your insulin
levels decrease. As your insulin levels decrease, therefore,
you have less mitogenic stimulation on the cancer cells
and this is one way, perhaps, you can reduce the tumor.Correspondence: nav@northwestern.edu
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unless otherwise stated.The second effect - and the two effects are not neces-
sarily mutually exclusive - is that the metformin actually
gets into the cancer cells: that there are transporters that
allow metformin to accumulate in cancer cells. And then
in the cancer cells it would hit some target and that
would then stop the cells from proliferating. Now, what
that target is has been elusive. People have been trying
to figure this out. We recently looked at the literature
and decided that the most promising target in cancer
cells has been mitochondrial complex I. I worked with
my group to come up with some ways to test whether
complex I inhibition was necessary for the anti-tumor
effects. The data suggested they were [2].
So I think it’s possible there are two mechanisms. One
is metformin hits the insulin and decreases insulin levels,
so you have less of a mitogenic stimulation to the PI3-
kinase pathway. The other one is - it gets eventually into
the mitochondria to inhibit complex I. There could be
other targets in mitochondria, including one that Gerry
Shulman’s lab has proposed, which is glycerol-3-phosphate
dehydrogenase [3]. This applies more to the effects of met-
formin on gluconeogenesis. Whether that’s related to anti-
cancer effects, we don’t know. But basically, you could haveThis is an Open Access article distributed under the terms of the Creative
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ect, through insulin, and direct through complex I or per-
haps other targets in the mitochondria.
Because of the interest in anti-cancer effects of
metformin there have been clinical trials, but
they’ve had inconclusive - or perhaps I should
say inconsistent - results between one trial and
another. It’s not clear that it actually works.
Why not?
Michael Pollak makes a great point when he says the
problem with metformin is it’s cheap, it’s widely avail-
able, it has a great safety profile, and anyone can use it.
That’s a problem?
Yes, because what you have is a rush to do clinical trials
because there is almost no barrier to entry. In fact, if
you Google metformin as a cancer patient, you might
find some data on it and you could say to your doctor, 'I
want to be put on Metformin', and your doctor would
have no reason to say no. As opposed to conventional
drug development - this is done very carefully: they do
toxicity studies; they carefully rationalize who should get
the treatment. Here there’s no rationalization. It’s there
for all comers, right? But of course if you don’t know
the mechanism then it makes it very difficult to know
who’s going to benefit.
So with the knowledge that we think we have now about
metformin and how it may work by these two mecha-
nisms - the insulin receptor-dependent mechanism and
the one that goes through mitochondrial complex I - you
can now take biopsies and actually characterize the tumor
cells with these two rationales in mind.
You’d want to look at four parameters, I would say.
One parameter is: are the tumor cells insulin receptor-
positive or IGF - insulin growth factor receptor - posi-
tive? Second, does the patient have high levels of insulin?
And then when they get on metformin, do those levels
of insulin come down? What happens to the receptor -
is it still there after metformin treatment?
The third parameter is critical to the cell autonomous
function, where the question is whether the metformin
would get into the cell and get access to the mitochon-
drial respiratory complex. You need the right trans-
porters, in this case organic cation transporters. There
are three of them. Again, with modern technology you
can see - are the tumor cells positive for those trans-
porters? If they are, then metformin can accumulate in
the cell.
Then, fourth, you have to get into the mitochondria as
well. You can look for metabolic signatures - as I call
them, the ox-phos, the oxidative phosphorylation meta-
bolic signatures. Some tumor cells might have a more
robust ox-phos metabolic signature or maybe they’re notas dependent on glucose, they’re not as PET-positive for
glucose.
So you can imagine now - if I was designing a clinical
trial, I’d want to know the insulin levels, the insulin re-
ceptor, the organic cation transporters, and a signature
of mitochondrial and glycolytic metabolic function. And
then - let’s see what happens. If you have all four then
you have multiple ways metformin could affect tumor
growth.
I would start with that, but now we can also think of
what rational therapeutic combinations would work. Be-
cause no one single agent works. Most people will try
chemotherapy, and I can tell you it’s not clear whether
chemotherapy is the best thing with metformin. Maybe
it is initially. But a lot of the chemotherapeutic drugs
work through reactive oxygen species (ROS). Metformin
acting cell autonomously can either increase or decrease
ROS: maybe metformin can in some cases mitigate the
effects of chemotherapy by not allowing ROS generation,
or it may in some cases increase ROS generation. So it
gets very muddled. But what’s clear is that decreasing
your ability to take up glucose, for example, would shut
off or decrease glycolysis, and metformin would decrease
ATP production from mitochondria. With the two to-
gether, there’s very little energy. Even a cancer cell can’t
get around that, if you block both of the ways to gener-
ate energy.
This is why I always tell people at my own university -
the clinicians - that it pays to know the mechanism be-
cause then we can perhaps advise them on rational ways
to go about clinical trials. That’s a basic scientist speak-
ing not a clinician! Perhaps a bit biased.
From a practical point of view, what evidence is
there for real effects in vivo of bigaunides,
including metformin, on tumor growth?
In an experimental setting, in the laboratory setting, there
have been quite a number of studies done in mouse
models of cancer where you put the mouse on metformin
and it diminishes tumor growth. We recently replaced
mitochondrial respiratory complex I function in mice with
a single yeast protein which can confer some of the com-
plex I activities, but is resistant to metformin [3]. In those
mice, the tumors still grew out in the presence of metfor-
min, because they had, essentially, an intact protein to re-
place complex I activity.
So we think complex I is necessary for metformin’s
anti-tumor effects in vivo. But there have been questions
about whether the concentrations of metformin that people
like myself have used in in vivo studies, or that Craig
Thompson’s used - he had a beautiful paper six or seven
years ago that got the field excited - whether they are clinic-
ally relevant concentrations. There are those who would
argue that we’re using, in the mouse, supraphysiological
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cokinetic analysis - perhaps some of us in the field should
just go back and do some real pharmacokinetics on metfor-
min at the concentrations that we’re delivering to the mice
in the plasma, but more importantly the tumor. You know,
grind up the tumor, figure out how much got in. To get
some rough estimates.
Something that you have to remember: even if you
start clinically with somewhere like 20 micromolar in
the plasma, the way that metformin gets into the mito-
chondria is based on the mitochondrial membrane po-
tential. So of that 20 micromolar in the plasma, the
amount that would accumulate in the mitochondrial
matrix would be almost 100 times more. Or 1,000 times
more. That’s important because you go from 20 micro-
molar to 20 millimolar in the matrix, if it’s a thousand-
fold increase. Because metformin - as very elegant work
from Judy Hirst has pointed out - is a weak inhibitor of
complex I - something like 20 millimolar, if I recall cor-
rectly from her talk at this meeting is the IC50 [4]. You
need millimolar to get in, but because of the membrane
potential - you can really, really enrich metformin. So
when people say, 'OK, 20 micromolar, but you need 20
millimolar', we have a good answer to that, because of
enrichment by the membrane potential.
Nevertheless, I think - again, because it’s a cheap drug,
we’ve used it for years - no one’s really answered those
questions: what is the clinical concentration? We use the
anti-diabetic dose in patients for cancer therapy in the
current clinical trials. Maybe we need to use higher
doses than the anti-diabetic dosing for metformin as an
anti-cancer agent. What’s interesting is that one of the
cancers metformin works best in is colon cancer, both
experimentally and epidemiologically. This makes good
sense because metformin does accumulate at very high
levels in the colon compared to other places.
So this is an important question and the debate con-
tinues. I think, in the end, there is a direct target in the
tumor cell; it’s not all insulin and organismal metabolism
that explains the epidemiology. As long as the tumor cell
has the transporters, it can take it up, get it into the
mitochondria, and then it can inhibit ATP or ROS pro-
duction and make the cells anti-proliferative.
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